Recently in Cell Metabolism, Ozcan et al. used preclinical and clinical data to suggest that alternate-day fasting may exacerbate the cardiotoxic effects of doxorubicin through the TFEB/GDF15 pathway, leading to myocardial atrophy and impaired cardiac function. The link between caloric intake, chemotherapy-induced cachexia, and cardiotoxicity warrants more clinical attention.
Keywords: alternate-day fasting; cardiotoxicity; doxorubicin; intermittent fasting.
Copyright © 2023 Elsevier Inc. All rights reserved.